Innovative Drugs for Neurological Disorders Discover
NX210 a multifunctional peptide is already GMP manufactured. Lead Product
A Clinical Stage Company Focus on Diseases
A Large Broad of Applications Our science

Our vocation

NEURONAX is a biopharmaceutical company based in Clermont-Ferrand and Lyon (France).

Our vocation is to develop first-in-class innovative drugs to treat patients with traumatic or severe neurological disorders with high unmet medical needs. Our ambition is to improve the recovery of the functionality and the quality of life for patients.

Our lead product (NX210) is a very promising drug with a high potential in many neurological disorders. This is a peptide with multi-functional action and its efficacy is supported by several pre-clinical proof of concept studies. We observed in vivo its capacity to regrow the nerve fibers after traumatic spinal cord injuries and to support functional recovery. The properties of NX210, and its patented analogs, have driven us with a strong rational to investigate in neurological disorders as Multiple Sclerosis, Alzheimer, Parkinson,..

A Phase I clinical trial in patients with Spinal Cord Injury is now authorized by French and Belgian Health Authorities.

Discovery

The interaction between glia and neurons is essential in development, function and repair of the central nervous system (CNS). In fact, signaling of glia is critical for axonal guidance and synaptogenesis at early developmental stages, whereas glial cells play a prominent role in the pathology of...

Learn more

NX210

NX210 is a patented peptide deduced from the thrombospondin repeat domains (TSRs) of the SCO-spondin, and a first-in class multi-functional agent able to prevent neural cell death and to promote neurite outgrowth. Our data show that NX210 is able to promote neurite fasciculation and...

Learn more

Diseases focus

Neurological disorders are diseases of the central and peripheral nervous system including epilepsy, Alzheimer disease and other dementias, Parkinson’s disease, multiple sclerosis, and other myelin disorders, but also cerebrovascular diseases like stroke, neuroinfections, brain tumors and trau...

Learn more

News

NEURONAX at Neuro Advance Boston

Neuro Advance Boston is an off-the-record forum that brings together CMOs, CSOs, CEOs, and Heads of Neuro from top biopharmaceutical companies in the neuroscience and pain management space. Dr Yann Godfrin, Chief Executive Officer, will attend the conference on October 11th 2017 at Harvard Medical School .

NEURONAX supports IRME

In coherence with its vocation , Neuronax supports the Institute for Research on Spinal Cord and Encephalon (IRME). The mission of … Read more

NEURONAX at Bio-Europe 2016

NEURONAX is present in Biotechnology partnering Conference Bio-Europe in Cologne, 7-9 November 2016. NEURONAX’s CEO, Dr. Yann Godfrin and Founder … Read more